Federal Circuit Dismisses Genentech v. Dr. Reddy’s CD20 Cancer Therapy Patent Appeal
What would you like to do next?
Explore the implications of this landmark biopharma ruling:
📋 Case Summary
| Case Name | Genentech, Inc. et al. v. Dr. Reddy’s Laboratories, Ltd. |
| Case Number | 24-1046 (Fed. Cir.) |
| Court | Federal Circuit, Appeal from D.C. Circuit |
| Duration | Oct 2023 – Jan 2025 1 year 3 months |
| Outcome | Defendant Win – Patent Unpatentable |
| Patents at Issue | |
| Accused Products | Generic anti-CD20/BCL-2 combination therapy |
Case Overview
The Parties
⚖️ Plaintiff
Global leaders in oncology biologics (Genentech, Hoffmann-La Roche) and BCL-2 inhibitor technology (AbbVie) with significant commercial interests in hematological oncology.
🛡️ Defendant
Major global generic and biosimilar pharmaceutical company with active ANDA and patent challenge pipelines.
The Patent at Issue
This case centered on U.S. Patent No. US10993942B2, covering a combination therapy pairing a Type II anti-CD20 antibody with a selective BCL-2 inhibitor.
- • US10993942B2 — Combination therapy for B-cell malignancies
Developing a similar combination therapy?
Check if your biopharma product might infringe this or related patents.
The Verdict & Legal Analysis
Outcome
The Federal Circuit issued a clean dismissal, affirming the patent’s unpatentability. No damages or injunctive relief were awarded, marking a complete defendant win.
Key Legal Issues
The dismissal was grounded in a finding of unpatentability, likely stemming from obviousness challenges under 35 U.S.C. § 103, particularly given the extensive prior art in anti-CD20 and BCL-2 inhibitor technologies.
Drafting biopharma combination patents?
Learn from this case. Use AI to draft stronger claims that can withstand validity challenges.
Power Your Patent Strategy with Eureka IP
From novelty searches to patent drafting, Eureka’s AI-powered tools help you navigate the patent landscape with confidence.
⚠️ Freedom to Operate (FTO) Analysis for Biopharma
This case highlights critical IP risks in biopharmaceutical combination therapies. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications for biopharma IP strategy.
- Analyze validity risks for combination therapy claims
- See trends in biopharma patent invalidations
- Understand Federal Circuit precedents on obviousness
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own biopharmaceutical product.
- Input your therapy description or technical features
- AI identifies potentially blocking patents (US10993942B2 and others)
- Get actionable risk assessment report for biopharma
High Risk Area
Biopharma combination therapy claims
1 Patent Invalidated
US10993942B2 (anti-CD20/BCL-2)
Strategic Implications
Reassess obviousness of combination claims
✅ Key Takeaways for Biopharma IP
For Patent Attorneys & Litigators
Federal Circuit affirmed unpatentability of combination therapy claims — review your oncology combination portfolios for similar vulnerabilities.
Search related case law →Multi-plaintiff consolidation strategies do not insulate combination patents from invalidity.
Explore precedents →For R&D Leaders & Researchers
Combination therapy development pathways benefit from early patent landscaping to identify unpatentability risks in prospective IP.
Start FTO analysis for my product →Document unexpected results and synergistic data contemporaneously to support patentability arguments if challenged.
Try AI patent drafting →Ready to Strengthen Your Patent Strategy?
Join thousands of IP professionals using Eureka to conduct prior art searches, draft patents, and analyze competitive landscapes.